drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody (biologic)
drug_description
Humanized anti-EGFR IgG1 monoclonal antibody that binds EGFR, blocks ligand-induced signaling (e.g., RAS–RAF–MEK–ERK; PI3K–AKT), reduces proliferation/survival, may mediate ADCC, and can enhance radiosensitization.
nci_thesaurus_concept_id
C2733
nci_thesaurus_preferred_term
Nimotuzumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.
drug_mesh_term
Nimotuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-EGFR IgG1 monoclonal antibody that binds the extracellular domain of EGFR, blocks ligand-induced receptor activation and downstream signaling (RAS–RAF–MEK–ERK; PI3K–AKT), reducing tumor cell proliferation and survival; may also mediate Fc-dependent ADCC and enhance radiosensitization.
drug_name
Nimotuzumab
nct_id_drug_ref
NCT06333821